Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PIMECROLIMUS Cause Drug ineffective for unapproved indication? 55 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 55 reports of Drug ineffective for unapproved indication have been filed in association with PIMECROLIMUS (Pimecrolimus). This represents 4.1% of all adverse event reports for PIMECROLIMUS.

55
Reports of Drug ineffective for unapproved indication with PIMECROLIMUS
4.1%
of all PIMECROLIMUS reports
0
Deaths
0
Hospitalizations

How Dangerous Is Drug ineffective for unapproved indication From PIMECROLIMUS?

Of the 55 reports.

Is Drug ineffective for unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PIMECROLIMUS. However, 55 reports have been filed with the FAERS database.

What Other Side Effects Does PIMECROLIMUS Cause?

Drug ineffective (349) Treatment failure (139) Psoriasis (114) Off label use (113) Pruritus (94) Erythema (89) Product use in unapproved indication (86) Rash (82) Application site pain (72) Therapeutic product effect incomplete (65)

What Other Drugs Cause Drug ineffective for unapproved indication?

GABAPENTIN (5,231) METHOTREXATE (2,513) DICLOFENAC (2,154) RITUXIMAB (1,776) LIDOCAINE (1,761) METHYLPREDNISOLONE (1,750) PREDNISONE (1,598) MYCOPHENOLATE MOFETIL (1,596) HUMAN IMMUNOGLOBULIN G (1,527) DEXAMETHASONE (1,302)

Which PIMECROLIMUS Alternatives Have Lower Drug ineffective for unapproved indication Risk?

PIMECROLIMUS vs PIMOZIDE PIMECROLIMUS vs PINAVERIUM PIMECROLIMUS vs PINDOLOL PIMECROLIMUS vs PIOGLITAZONE PIMECROLIMUS vs PIPAMPERONE

Related Pages

PIMECROLIMUS Full Profile All Drug ineffective for unapproved indication Reports All Drugs Causing Drug ineffective for unapproved indication PIMECROLIMUS Demographics